Loading…
Galmed Pharmaceuticals Ltd. is projected to rise to $0.8083 by 2027, a +30% move from its current price of $0.62. GLMD is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.5928 | $0.6201 | $0.6486 | +0.01% |
| May 30 | $0.582 | $0.6201 | $0.6608 | +0.02% |
| May 31 | $0.5738 | $0.6202 | $0.6704 | +0.03% |
| Jun 1 | $0.567 | $0.6203 | $0.6786 | +0.04% |
| Jun 2 | $0.561 | $0.6203 | $0.6859 | +0.05% |
| Jun 3 | $0.5557 | $0.6204 | $0.6925 | +0.06% |
| Jun 4 | $0.5509 | $0.6205 | $0.6987 | +0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.5509 | $0.6205 | $0.6987 | +0.07% |
| Week 2 | $0.5248 | $0.6209 | $0.7345 | +0.15% |
| Week 3 | $0.5058 | $0.6214 | $0.7634 | +0.22% |
| Week 4 | $0.4903 | $0.6218 | $0.7886 | +0.29% |
| Week 5 | $0.4771 | $0.6223 | $0.8117 | +0.37% |
| Week 6 | $0.4654 | $0.6227 | $0.8331 | +0.44% |
| Week 7 | $0.455 | $0.6232 | $0.8534 | +0.51% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Galmed Pharmaceuticals Ltd. is a biopharmaceutical company focused on developing therapeutics for the treatment of liver diseases and related indications. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.
The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis.
It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model.
Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Galmed Pharmaceuticals Ltd. (GLMD) is a healthcare company focused on liver disease therapeutics, including Aramchol in Phase III for NASH. The stock trades with a current price of $0.5801 and has a market cap of $3.83M, ranking 5399 by market capitalization.
The company’s pipeline includes Amilo-5MER and MyBiotics in pre-clinical stages, along with collaborations and licensing arrangements in Korea and with AI/tissue-model partners. The current price and near-term indicators place GLMD in a small-cap, high-variance investment space with multiple ongoing programs and partnerships.
A major floor 27.5% below — a decisive break under it would weaken the trend.
The nearest floor, 9.7% below — buyers have tended to step in here.
The nearest ceiling, 21.9% above — a clean break opens room to run.
A major ceiling 37.6% above — clearing it would confirm fresh momentum.
Key GLMD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GLMD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.6028 | Buy | $0.6077 | Buy |
| MA 10 | $0.6026 | Buy | $0.6038 | Buy |
| MA 20 | $0.5967 | Buy | $0.6074 | Buy |
| MA 50 | $0.6151 | Buy | $0.627 | Sell |
| MA 100 | $0.6566 | Sell | $0.7134 | Sell |
| MA 200 | $0.9584 | Sell | $1.06 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.46 | Neutral |
| Stoch RSI (14) | 64.87 | Neutral |
| CCI (20) | 75.98 | Neutral |
| Williams %R (14) | -46.43 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 1.47 | Buy |
| Bollinger %B (20,2) | 0.74 | Neutral |
| Stochastic %K (14) | 53.57 | Neutral |
| TRIX (15) | -0.23 | Sell |
| Awesome (5,34) | -0.04 | Sell |
| Ultimate (7,14,28) | 52.44 | Neutral |
| Momentum (10) | 0.04 | Buy |
| Aroon Osc (25) | -24.00 | Sell |
| Hull MA (9) | 0.61 | Buy |
| ADX (14) | 10.16 | Neutral |
| ATR (14) | 0.02 | Info |
The near-term technical picture is Bearish. RSI14 is 50, with the 50-day SMA at $0.6151 and the 200-day SMA at $0.9662. There is support at $0.56 and resistance at $0.76, framing a close-to-mid-range setup.
The stock has traded within a 30-day range of $0.4341 to $0.7753, suggesting limited volatility within that window. Annualized volatility is high, at 80, reflecting the risk profile of the small-cap name.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.475 | $0.62 | $0.8808 | 0% | Neutral | |
| $0.6009 | $0.8083 | $1.17 | +30% | Bullish | |
| $0.5898 | $0.8323 | $1.27 | +34% | Bullish | |
| $0.5801 | $0.853 | $1.36 | +38% | Bullish | |
| $0.498 | $0.7599 | $1.25 | +23% | Bullish | |
| $0.4298 | $0.6788 | $1.16 | +9% | Neutral | |
| $0.5354 | $0.8738 | $1.53 | +41% | Bullish | |
| $0.6174 | $1.04 | $1.86 | +68% | Bullish | |
| $0.6286 | $1.09 | $2.00 | +76% | Bullish | |
| $0.605 | $1.08 | $2.02 | +74% | Bullish | |
| $0.7463 | $1.53 | $3.12 | +147% | Bullish | |
| $0.9817 | $2.18 | $5.01 | +252% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.475 | $0.62 | $0.7287 | +0.00% |
| June 2026 | $0.4968 | $0.5917 | $0.7276 | -4.56% |
| July 2026 | $0.5182 | $0.6259 | $0.7864 | +5.78% |
| August 2026 | $0.5418 | $0.6618 | $0.8452 | +5.73% |
| September 2026 | $0.5211 | $0.6424 | $0.8314 | -2.94% |
| October 2026 | $0.512 | $0.6365 | $0.8338 | -0.91% |
| November 2026 | $0.5336 | $0.6684 | $0.8847 | +5.01% |
| December 2026 | $0.5223 | $0.6589 | $0.8808 | -1.42% |
Click any year to see its month-by-month GLMD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Galmed Pharmaceuticals Ltd.'s 2026 outlook centres on $0.62, within a $0.475 to $0.8808 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, GLMD could reach as high as $1.17, with a base case around $0.8083 and support toward $0.6009 — roughly +30% from $0.62. Momentum favours further upside here.
Expect GLMD to range from $0.5898 to $1.27 through 2028. The $0.8323 average target implies a +34% move from current prices. That is up +3% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The GLMD price prediction for 2029 points to an average of $0.853 (low $0.5801, high $1.36) — a potential gain of +38% on today's $0.62. Momentum favours further upside here.
In 2030, GLMD is projected to trade between $0.498 and $1.25, averaging $0.7599 — a potential gain of +23% from today's $0.62. That is -11% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
Galmed Pharmaceuticals Ltd.'s 2031 outlook centres on $0.6788, within a $0.4298 to $1.16 range. That is -11% versus the projected 2030 average. That marks a +9% change versus current levels. Price action looks broadly range-bound.
By 2032, GLMD could reach as high as $1.53, with a base case around $0.8738 and support toward $0.5354 — roughly +41% from $0.62. Buyers look set to stay in control over this stretch.
Expect GLMD to range from $0.6174 to $1.86 through 2033. The $1.04 average target implies a +68% move from current prices. That is up +19% on the projected 2032 average. Momentum favours further upside here.
The GLMD price prediction for 2034 points to an average of $1.09 (low $0.6286, high $2.00) — a potential gain of +76% on today's $0.62. Buyers look set to stay in control over this stretch.
In 2035, GLMD is projected to trade between $0.605 and $2.02, averaging $1.08 — a potential gain of +74% from today's $0.62. That is -1% versus the projected 2034 average. Momentum favours further upside here.
Galmed Pharmaceuticals Ltd.'s 2040 outlook centres on $1.53, within a $0.7463 to $3.12 range. That is up +42% on the projected 2035 average. That marks a +147% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, GLMD could reach as high as $5.01, with a base case around $2.18 and support toward $0.9817 — roughly +252% from $0.62. Momentum favours further upside here.
Investing $1,000 in GLMD today (≈ 1,612.903226 GLMD) could be worth
$3,518.48
+$2,518.48 (+252%) by 2050 · US Dollar
Based on the average projected GLMD price of $2.18 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GLMDwould be worth at today's price.
$1,000 invested in GLMD on May 27, 2025 (≈ 675.675667 GLMD) would be worth
$418.92
-$581.08 (-58.1%) today · 0.42× · US Dollar
Based on a GLMD entry price of $1.48 vs. today's $0.62.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.604 | $1,026.49 | +2.6% |
| 1 month ago | $0.624 | $993.59 | -0.6% |
| 3 months ago | $0.65 | $953.85 | -4.6% |
| 6 months ago | $0.94 | $659.57 | -34.0% |
| 1 year ago | $1.48 | $418.92 | -58.1% |
| All time (5.0y) ago | $473.4 | $1.31 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GLMD forecast.
Our base-case forecast reaches $1.20 around 2040.
Implied market cap at $1.20: $7.92M
The year-by-year forecast shows divergent price paths with overall bullish momentum in the later years. For 2026, the average price is $0.5801 with a min of $0.475 and a max of $0.7982, and a 0 ROI with neutral sentiment.
In 2027, the average rises to $0.7407 (min $0.5522, max $1.07), with a 27.7 ROI and bullish sentiment. The 2028 forecast places the average at $0.7762 (min $0.5523, max $1.18) and a 33.8 ROI, also bullish. By 2030, the average is $0.6982 (min $0.4604, max $1.15) with a 20.4 ROI and bullish sentiment.
The pattern continues with 2031 at $0.6249 average (min $0.3985, max $1.06; 7.7 ROI, neutral), 2032 at $0.7719 (min $0.4768, max $1.34; 33.1 ROI, bullish), and 2033 at $0.9299 (min $0.5573, max $1.65; 60.3 ROI, bullish). 2034 shows $0.9823 average (min $0.5719, max $1.79; 69.3 ROI, bullish) and 2035 at $0.9643 (min $0.5457, max $1.79; 66.2 ROI, bullish).
Long-term horizons project stronger upside with 2040 averaging $1.37 (min $0.6766, max $2.76; 135.6 ROI, bullish) and 2050 averaging $1.85 (min $0.834, max $4.21; 219.5 ROI, bullish). These are estimates and not guarantees, reflecting model projections with inherent uncertainties and risk volatility for this small-cap equity.
Tap a question to reveal the answer.
In 2030, the avg price is $0.6982, with a min of $0.4604 and a max of $1.15; ROI 20.4; sentiment bullish.
Forecasts show bullish sentiment from 2027 onward with rising averages and higher potential highs, e.g., max values above $1. The 2026 avg is $0.5801 with ROI 0 and neutral sentiment. As a small-cap stock with a market cap of $3.83M, it carries higher risk.
Yes. The forecast shows several years with max prices at or above $1, including 2027 ($1.07), 2028 ($1.18), 2032 ($1.34), 2033 ($1.65), 2034 ($1.79), 2040 ($2.76), and 2050 ($4.21).
The current price is $0.5801 and the market cap is $3.83M.
In 2050, the forecast shows an avg of $1.85, with a min of $0.834 and a max of $4.21; ROI 219.5; sentiment bullish.
Galmed Pharmaceuticals Ltd. Community Discussion
0Share your Galmed Pharmaceuticals Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.